Advisor profile · Dr David Brown
Drug discoveryexperience.Focused on T‑Booster.
Across more than 50 years in global pharma and biotechnology, Dr David Brown has helped move medicines from research to clinical proof. Since 2022, he has brought that judgement to AVIX Pharmaceuticals Limited, advising primarily on T‑Booster and Green Antibiotics.
THE ADVISORY JOURNEY
01
Global pharmaICI · Pfizer · Glaxo Wellcome · Roche
02
Biotech & translationCellzome · Crescendo · Healx
03
Since 2022 · United KingdomIndependent advisor to AVIX Pharmaceuticals
T‑BoosterPrimary advisory focus
Green AntibioticsAMR collaboration
50+ yearsDRUG DISCOVERY & PHARMA
ViagraCO-INVENTOR & PROGRAMME LEAD
2,000 staffROCHE DRUG DISCOVERY
Since 2022AVIX ADVISOR
01 · Experience brought to AVIX
Drug-discovery judgementbuilt at global scale.
Dr David Brown has spent more than 50 years across pharmaceutical research, biotechnology and company building. His career includes senior roles with ICI Pharmaceuticals/Zeneca, Pfizer, Glaxo Wellcome and Hoffmann-La Roche, followed by biotechnology leadership including President and Chief Executive of Cellzome AG.
At Pfizer, he was named a co-inventor on the patent for Viagra and led the programme from its early research through proof of clinical efficacy in human trials. He also played a pivotal role in the discovery of Relpax.
At Roche in Switzerland, he served as a director overseeing approximately 2,000 staff working in drug discovery across research sites in the United States, Europe and Asia. He later helped found biotechnology ventures including Crescendo Biologics and Healx.
02 · T‑Booster
Pharmaceutical disciplineapplied to T‑Booster.
T‑Booster is the centre of Dr Brown's advisory role with AVIX. He works with Dr Md Arif Sheikh to pressure-test the scientific logic, guide development thinking and help shape a credible route from formulation and human evidence towards partnership and market.
Scientific rationale
Challenge the core biological logic.Keep the product thesis science-led.Separate hypotheses from evidence.
Development strategy
Set formulation and evidence needs.Frame the clinical questions.Keep programme planning disciplined.
Human evidence
Interpret signals within study design.Separate promising signals from proof.Keep conclusions tied to the data.
Commercial pathway
Bring science into positioning.Support partnership decisions.Align market plans with evidence.
03 · Green Antibiotics
Drug-discovery disciplinefor antimicrobial resistance.
Alongside T‑Booster, Dr Brown collaborates with Dr Sheikh on Green Antibiotics — an AVIX programme exploring defined plant-derived antimicrobial combinations for animal health. His role is to bring drug-discovery discipline to the questions of screening, evidence, development strategy and translation.
Antibiotic Research UK
Served as Trustee and Science Committee Chair.Worked with UK experts on antimicrobial resistance.Brought independent scrutiny to the challenge.
OneWorld Health / PATH
Contributed to global-health drug development.Co-invented iOWH-032 for enteric disease.The programme progressed through Phase 1.
Green Antibiotics
Advises on scientific priorities and screening.Challenges evidence quality and development logic.Helps shape a credible path to translation.
For Dr Brown, T‑Booster and Green Antibiotics are different programmes with a shared requirement: scientific ideas must survive disciplined development before they deserve commercial confidence.
Visit Green Antibiotics ↗04 · Independent AVIX role
Independent judgement.Long-term involvement.
Since 2022, Dr Brown has advised AVIX Pharmaceuticals Limited in the UK, working closely with Dr Sheikh on T‑Booster and Green Antibiotics. His contribution spans scientific strategy, development thinking, marketing perspective and business-plan review.
The value of the relationship is independence as much as experience: Dr Brown provides challenge and judgement at decisions that affect scientific credibility and commercial readiness. At the time of this profile, he holds no financial stake in AVIX Pharmaceuticals Limited.